혈액 점도계 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Blood Viscometer Market Summary

The global blood viscometer market size was estimated at USD 1.62 billion in 2024 and is projected to reach USD 2.63 billion by 2033, growing at a CAGR of 5.63% from 2025 to 2033. The growth outlook by advancements in clinical diagnostics, the increasing prevalence of cardiovascular and hematological disorders, and the growing adoption of point-of-care testing technologies.

In April 2023, a study published in Clinical Hemorheology and Microcirculation examined blood rheology and nitric oxide levels in coronary artery disease patients. The findings showed that higher erythrocyte aggregation and lower NO levels were linked to poorer collateral vessel development in the heart. Innovation in blood viscometry is increasing, with modern instruments offering real-time measurement, minimal sample volume requirements, and enhanced sensitivity for non-Newtonian fluids. These advancements enable more precise rheology assessments, improve diagnostic accuracy in conditions such as diabetes, hyperviscosity syndromes, and thrombosis, and expand use in routine clinical testing.In December 2022, an article in the Biomedical Journal discussed how grounding, or direct contact with the Earth's surface, helps lower inflammation, stabilize heart rate, and improve flow. The study noted measurable improvements in zeta potential, suggesting reduced red blood cell aggregation, a factor directly linked to viscosity and its monitoring in clinical research.

The rising incidence of cardiovascular diseases, anemia, and coagulation disorders is fueling demand for accurate viscosity measurement tools. As these disorders often involve changes in blood flow properties, viscometers are increasingly used for patient risk assessment, treatment monitoring, and therapy optimization.In February 2025, the World Health Organization (WHO) reported that anemia affects 40% of young children, 37% of pregnant women, and 30% of women of reproductive age worldwide.

The shift toward decentralized, rapid diagnostic solutions is driving demand for compact, user-friendly viscometers that deliver instant results in point-of-care settings, such as ICUs and outpatient clinics. This trend supports early disease detection, aligns with personalized medicine, and promotes cost-efficient healthcare delivery, sustaining market growth. In October 2023, a study in the Journal of Applied Physics presented a magnetic falling-sphere viscometer that employs a magnetized sphere and fluxgate magnetometers to track its motion through fluid. The system requires only 15 ml of sample and determines viscosities from 200 to 3000 cP within seconds, achieving 3% precision.

Global Blood Viscometer Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global blood viscometer market report based on product, application, end use, and region.

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Capillary Viscometer
• Rotational Viscometer
• Vibrational / Oscillatory Viscometer
• Microfluidic Viscometer
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Clinical Diagnostics
• Hematology & Blood Research
• Point-of-Care Testing (POCT)
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Diagnostic Laboratories
• Research & Academic Institutes
• Pharmaceutical & Biotechnology Companies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. End use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Blood Viscometer Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of cardiovascular and metabolic disorders
    • 3.2.1.2. Shift toward advanced point-of-care and research diagnostics
    • 3.2.1.3. Healthcare infrastructure expansion and private lab proliferation
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High device cost and limited reimbursement support
    • 3.2.2.2. Lack of technical expertise and standardized protocols
  • 3.2.3. Competitive factors and strategies
    • 3.2.3.1. Clinical insights
    • 3.2.3.2. Emerging technologies
    • 3.2.3.3. Market appeal
    • 3.2.3.4. Product improvements and innovations
• 3.3. Blood Viscometer Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Technology landscape
• 3.5. Regulatory Framework
• 3.6. Case Study Analysis

Chapter 4. Blood Viscometer Market: Product Estimates & Trend Analysis

• 4.1. Definition and Scope
• 4.2. Product Market Share Analysis, 2024 & 2033
• 4.3. Segment Dashboard
• 4.4. Capillary Viscometer
  • 4.4.1. Capillary viscometer market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Rotational Viscometer
  • 4.5.1. Rotational viscometer market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Vibrational / Oscillatory Viscometer
  • 4.6.1. Vibrational / oscillatory viscometer market estimates and forecasts 2021 to 2033 (USD Million)
• 4.7. Microfluidic Viscometer
  • 4.7.1. Microfluidic viscometer market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Blood Viscometer Market: Application Estimates & Trend Analysis

• 5.1. Definition and Scope
• 5.2. Application Market Share Analysis, 2024 & 2033
• 5.3. Segment Dashboard
• 5.4. Clinical Diagnostics
  • 5.4.1. Clinical diagnostics market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Hematology & Blood Research
  • 5.5.1. Hematology & blood research market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Point-of-Care Testing (POCT)
  • 5.6.1. Point-of-care testing (POCT) market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Blood Viscometer Market: End Use Estimates & Trend Analysis

• 6.1. Definition and Scope
• 6.2. End Use Market Share Analysis, 2024 & 2033
• 6.3. Segment Dashboard
• 6.4. Hospitals & Diagnostic Laboratories
  • 6.4.1. Hospitals & diagnostic laboratories market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Research & Academic Institutes
  • 6.5.1. Research & academic institutes market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Pharmaceutical & Biotechnology Companies
  • 6.6.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Blood Viscometer Market: Regional Estimates & Trend Analysis by Product, Application and End Use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Middle East & Africa
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Vendor Landscape
  • 8.2.1. Key company market share analysis, 2024
  • 8.2.2. Anton Paar GmbH
    • 8.2.2.1. Overview
    • 8.2.2.2. Financial Performance
    • 8.2.2.3. Product Benchmarking
    • 8.2.2.4. Strategic Initiatives
  • 8.2.3. RheoSense, Inc.
    • 8.2.3.1. Overview
    • 8.2.3.2. Financial Performance
    • 8.2.3.3. Product Benchmarking
    • 8.2.3.4. Strategic Initiatives
  • 8.2.4. Benson Viscometers - Clinical Viscometers
    • 8.2.4.1. Overview
    • 8.2.4.2. Financial Performance
    • 8.2.4.3. Product Benchmarking
    • 8.2.4.4. Strategic Initiatives
  • 8.2.5. Beijing Steellex Scientific Instrument Co., Ltd.
    • 8.2.5.1. Overview
    • 8.2.5.2. Financial Performance
    • 8.2.5.3. Product Benchmarking
    • 8.2.5.4. Strategic Initiatives
  • 8.2.6. Health Onvector
    • 8.2.6.1. Overview
    • 8.2.6.2. Financial Performance
    • 8.2.6.3. Product Benchmarking
    • 8.2.6.4. Strategic Initiatives
  • 8.2.7. KYOTO ELECTRONICS MANUFACTURING CO., LTD.
    • 8.2.7.1. Overview
    • 8.2.7.2. Financial Performance
    • 8.2.7.3. Product Benchmarking
    • 8.2.7.4. Strategic Initiatives
  • 8.2.8. A&D Company, Limited
    • 8.2.8.1. Overview
    • 8.2.8.2. Financial Performance
    • 8.2.8.3. Product Benchmarking
    • 8.2.8.4. Strategic Initiatives
  • 8.2.9. AMETEK.Inc.
    • 8.2.9.1. Overview
    • 8.2.9.2. Financial Performance
    • 8.2.9.3. Product Benchmarking
    • 8.2.9.4. Strategic Initiatives
  • 8.2.10. Cannon Instrument Company.
    • 8.2.10.1. Overview
    • 8.2.10.2. Financial Performance
    • 8.2.10.3. Product Benchmarking
    • 8.2.10.4. Strategic Initiatives
  • 8.2.11. CSC Scientific Company, Inc.
    • 8.2.11.1. Overview
    • 8.2.11.2. Financial Performance
    • 8.2.11.3. Product Benchmarking
    • 8.2.11.4. Strategic Initiatives